• MyRepair Blood Test to Identify People at High Risk for Lung Cancer (No. T4-1033)

    Scientist: Zvi Livneh

    A novel diagnostic test to identify individuals with increased risk of lung cancer. Lung cancer is the number one killer among cancers, with 160,000 deaths/year in the USA and 1.6 million/year worldwide. Early detection of lung cancer increases 5-year survival rate from 4% to 54%. Moreover, the National Lung Cancer Trial ... Read more
  • Novel Aptamer for Cancer Therapy (No. T4-1633)

    Scientist: Yosef Yarden

    The ErbB family consists of four structurally related receptor tyrosine kinases. Excessive ErbB signaling is associated with enhanced tumorogenesis, and as such serves as a major therapeutic target in a wide array of solid tumor cancers. A member of this family, the human epidermal growth factor receptor 2 (ErbB-2/HER2), ... Read more
  • Novel Method for Diagnosing and Treating Relapsed Obesity (No. T4-1805)

    Scientist: Eran Segal

    Obesity is the health epidemic of the modern world, with nearly half the global adult population being categorized as obese. The consequences of said mass obesity is that it is overwhelming the medical systems all over the world, as obesity is linked to numerous diseases ranging from diabetes to cancer. The challenge is ... Read more
  • Novel Method for Diagnosis and Treating Cancer by Analyzing the Urea Cycle (No. T4-1872)

    Scientist: Ayelet Erez

    The urea cycle (UC) is an important metabolic pathway that takes place in the liver. A variety of enzymes, such as argininosuccinate synthase 1 (ASS1) and the trifunctional enzyme CAD, are involved in the UC, which converts excess nitrogen into urea. The UC produces various metabolites based on the balance between its co ... Read more
  • Novel Treatment for Lung Diseases by Allogeneic Cell Transplantation (No. T4-1868)

    Scientist: Yair Reisner

    The treatment of respiratory conditions is currently one of the major challenges to health care systems all over the world. The problem is that most therapeutics currently available for treating pulmonary indications are non-curative, and simply improve symptoms. Presently the only cure for late stage pulmonary diseases ... Read more
  • On-Chip Synthesis of Biomolecules (No. T4-1369)

    A simple, single-step biochip platform for synthesis of biomolecules. Biochip technology is used today in measuring passive probe-target interactions i.e. measurement of the abundance of specific biomolecules). This technology can now be extended to include complex and cascaded activities on the chip. The present immobil ... Read more
  • P38 and JNK Inhibitor as Potential Treatment for Various Pathologies (No. T4-1733)

    Scientist: Rony Seger

    Recently, Prof. Zeger and his team discovered a new level of regulation to stimulated transcription. They showed that ?-like importunes are central mediators of nuclear translocation of signaling proteins. Furthermore they identified the site of interaction and designed accordingly a peptide which was found to prevent nu ... Read more
  • Person-specific Assessment of Probiotics Responsiveness (No. T4-1895)

    Scientist: Eran Segal

    Dietary supplementation with commensal microorganisms, collectively termed probiotics, is a constantly growing market, estimated to exceed 69.3 billion USD by 2023. Probiotics are the third most commonly consumed dietary supplement after vitamin and mineral preparations. Claimed rationales for probiotics consumption by h ... Read more
  • rPTE with Potent Organophosphate (OPH) Activities (No. T4-1750)

    Scientist: Dan Tawfik

    Organophosphates are toxic compounds found in chemical warfare agents, such as nerve gases, and insect pesticides.Use of volatile nerve gas agents by terrorist organizations is a key concern of governments around the world. V-type nerve agents (e.g. VX, RVX, and CVX) are particularly toxic nerve gases, with an exceptiona ... Read more
  • SiRNA Proteasome Inhibitors for Cancer Theraphy (No. T4-1619)

    Scientist: Yosef Shaul

    Triple negative breast cancer (TNBC) is an aggressive type of breast cancer, representing over 10% of all breast cancer cases. TNBC is known for its high risk of relapse, poor survival prospects, and near zero survival rates once TNBC metastasizes. Due to the lack of molecular targets (estrogen, progesterone, and HER2 re ... Read more


Subscribe to Pharmaceuticals